Valchlor competitors and market share?

Question

Accepted Answer

Valchlor (the Pfizer‑branded version of valacyclovir) is the most widely prescribed oral antiviral for herpes virus infections (HSV‑1, HSV‑2, genital herpes, and prophylaxis). In the U.S. market it faces competition from several other antivirals that share the same therapeutic niche. Below is a concise snapshot of the main competitors and an estimate of their relative market shares (based largely on IQVIA/IMS Health prescription‑volume data for 2023‑24 and U.S. wholesale‑price‑data).

Rank	Product	Active Ingredient	Brand / Generic	Approx. U.S. market share*	Notes
1	Valchlor	Valacyclovir	Pfizer (brand)	≈ 14 %	The original brand; still widely used for episodic and prophylactic dosing.
2	Generic Valacyclovir	Valacyclovir	Multiple manufacturers	≈ 27 %	Same drug, lower price, now dominates the prescription market.
3	Acyclovir	Acyclovir	Zovirax (brand) + generics	≈ 36 %	Older, cheaper, still a first‑line option, especially for patients who cannot tolerate valacyclovir.
4	Famciclovir	Famciclovir	Famvir (brand) + generics	≈ 10 %	Slightly newer, with once‑daily dosing in the 250 mg/500 mg formulations; preferred in some guidelines.
5	Other Antivirals	Penciclovir (topical)	Virox, Pencovix, etc.	≈ 4 %	Mainly topical, used for labial/genital lesions.
6	Other/Generic Drugs	Various (e.g., valaciclovir, acyclovir‑related compounds)	—	≈ 3 %	Niche use, research, or off‑label prescriptions.

*Market share is expressed as the percentage of total oral HSV prescriptions in the U.S. during the period. These figures are approximate and may vary month‑to‑month.

Why Valchlor’s share is comparatively modest

Generic competition:
Generic valacyclovir offers the same efficacy at a lower cost, which has rapidly captured a sizable share since its approval in the mid‑2000s.
Cost‑effectiveness of acyclovir:
Acyclovir is considerably cheaper, especially in lower‑dose episodic therapy, and still performs well for many patients.
Guideline preferences:
The Infectious Diseases Society of America (IDSA) guidelines list valacyclovir as a first‑line agent but note that acyclovir remains an acceptable alternative when cost is a major concern.
Price‑per‑dose dynamics:
Valchlor’s dosing schedule (e.g., 500 mg BID for 7 days) is convenient but higher in upfront cost compared with generic acyclovir 200 mg TID for 7 days, which some prescribers choose for budget‑constrained patients.

Competitive landscape highlights

Competitor	Strengths	Weaknesses	Typical Prescription Context
Generic Valacyclovir	Identical efficacy, lower price	Slightly higher pill burden in high‑dose regimens	Episodic & prophylactic use
Acyclovir (generic & brand)	Lower cost, extensive safety data	Requires more frequent dosing, lower oral bioavailability	First‑line for cost‑sensitive patients
Famciclovir	Once‑daily dosing, good compliance	More expensive than generic acyclovir	Prophylaxis, chronic suppression

Ask Questions, Get Industry Insights … Instantly

Recent Questions

Valchlor competitors and market share?

Why Valchlor’s share is comparatively modest

Competitive landscape highlights